Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer

Fulvestrant is a selective oestrogen receptor downregulator, with a distinct mode of action  [1]. Fulvestrant is an effective treatment option in postmenopausal women with advanced hormone receptor–positive breast cancer [2,3]. After the recent publications of pivotal randomised trial results assessing fulvestrant in combination with CDK (Cyclin-dependent kinase) 4/6 inhibitors or alpel isib, fulvestrant is likely to be increasingly used in women with advanced oestrogen receptor-positive breast cancer.

Source: European Journal of Cancer - January 12, 2020 Category: Cancer & Oncology Authors: E. Samuel, C. Chiang, R. Jennens, D. Faulkner, P.A. Francis Tags: Letter to the Editor Source Type: research